These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 11352870)
1. CYP17 genotype and ovarian cancer: a null case-control study. Goodman MT; McDuffie K; Guo C; Terada K; Donlon TA Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):563-4. PubMed ID: 11352870 [No Abstract] [Full Text] [Related]
2. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Goodman MT; McDuffie K; Kolonel LN; Terada K; Donlon TA; Wilkens LR; Guo C; Le Marchand L Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):209-16. PubMed ID: 11303589 [TBL] [Abstract][Full Text] [Related]
3. Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Goodman MT; Tung KH; McDuffie K; Wilkens LR; Donlon TA Nutr Cancer; 2003; 46(1):23-9. PubMed ID: 12925300 [TBL] [Abstract][Full Text] [Related]
4. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959 [TBL] [Abstract][Full Text] [Related]
5. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Verla-Tebit E; Wang-Gohrke S; Chang-Claude J Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450 [TBL] [Abstract][Full Text] [Related]
6. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Chang JH; Gertig DM; Chen X; Dite GS; Jenkins MA; Milne RL; Southey MC; McCredie MR; Giles GG; Chenevix-Trench G; Hopper JL; Spurdle AB Breast Cancer Res; 2005; 7(4):R513-21. PubMed ID: 15987458 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Garner EI; Stokes EE; Berkowitz RS; Mok SC; Cramer DW Cancer Res; 2002 Jun; 62(11):3058-62. PubMed ID: 12036914 [TBL] [Abstract][Full Text] [Related]
8. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. McKean-Cowdin R; Feigelson HS; Pike MC; Coetzee GA; Kolonel LN; Henderson BE Cancer Res; 2001 Feb; 61(3):848-9. PubMed ID: 11221867 [TBL] [Abstract][Full Text] [Related]
9. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806 [TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247 [TBL] [Abstract][Full Text] [Related]
11. A polymorphism in the CYP17 gene increases the risk of breast cancer. Feigelson HS; Coetzee GA; Kolonel LN; Ross RK; Henderson BE Cancer Res; 1997 Mar; 57(6):1063-5. PubMed ID: 9067272 [TBL] [Abstract][Full Text] [Related]
12. Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women. Onland-Moret NC; van Gils CH; Roest M; Grobbee DE; Peeters PH Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):815-20. PubMed ID: 15824149 [TBL] [Abstract][Full Text] [Related]
13. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer associated with CYP17 genotype. Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544 [TBL] [Abstract][Full Text] [Related]
15. A polymorphism in the CYP17 gene is associated with male breast cancer. Young IE; Kurian KM; Annink C; Kunkler IH; Anderson VA; Cohen BB; Hooper ML; Wyllie AH; Steel CM Br J Cancer; 1999 Sep; 81(1):141-3. PubMed ID: 10487625 [TBL] [Abstract][Full Text] [Related]
16. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Tigli H; Yazici H; Dalay N Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129 [TBL] [Abstract][Full Text] [Related]
17. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Mitrunen K; Jourenkova N; Kataja V; Eskelinen M; Kosma VM; Benhamou S; Vainio H; Uusitupa M; Hirvonen A Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1343-8. PubMed ID: 11142420 [TBL] [Abstract][Full Text] [Related]
18. [A case-control study on genetic polymorphism of CYP17 MspA(1)I and its association with endometrial cancer risk]. Gao J; Xiang YB; Xu WH; Cheng JR; Cai QY; Shu XO; Gao YT Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):266-9. PubMed ID: 17760252 [TBL] [Abstract][Full Text] [Related]
19. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Henningson M; Johansson U; Borg A; Olsson H; Jernström H Mol Hum Reprod; 2007 Apr; 13(4):231-6. PubMed ID: 17307805 [TBL] [Abstract][Full Text] [Related]
20. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Hou L; Xu J; Gao YT; Rashid A; Zheng SL; Sakoda LC; Shen MC; Wang BS; Deng J; Han TQ; Zhang BH; Meyers DA; Fraumeni JF; Hsing AW Int J Cancer; 2006 Jun; 118(11):2847-53. PubMed ID: 16381022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]